Regeneron (REGN) Reports REGN5678 Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRP
August 3, 2022 6:25 AM EDTFirst clinical data from ongoing Phase 1/2 trial show dose-dependent anti-tumor activity for investigational REGN5678 (PSMAxCD28) when combined with standard dose Libtayo, suggesting potential to overcome mCRPC resistance to PD-1 inhibition
Anti-cancer activity correlated with immune-related adverse events
These data provide early evidence and proof of principle for Regeneron's broader costimulatory bispecific platform, which includes three CD28 bispecifics in ongoing clinical trials and additional candidates in preclinical development
TARRYTOWN, N.Y., Aug. 3, 2022 /PRNewswire/ --Â Regeneron Pharmaceuticals, Inc. (NASDAQ:... More
